Teplizumab Beneficial for Preserving Beta-Cell Function in Pediatric T1D

For children and adolescents with newly diagnosed type 1 diabetes, two 12-day courses of teplizumab show benefit for preservation of beta (β)-cell function.

Related Keywords

New Jersey ,United States ,Netherlands ,Eleanorl Ramos ,Provention Bio ,Red Bank ,International Society For Pediatric ,Healthday News ,New England Journal ,International Society ,Adolescent Diabetes ,